细胞免疫治疗在中晚期肝癌的应用效果观察  

Effect Observation of Cellular Immunotherapy in Treatment of Patients with Middle-advanced Hepatocellular Carcinoma

作　　者：武振明[1] 史素梅[1] 王凌凌[1] 郭茜[1] 王帅兵[1] 齐秀恒[1] 

机构地区：[1]中国石油天然气集团公司中心医院肿瘤科,河北廊坊065000

出　　处：《解放军医药杂志》2018年第2期9-12,共4页Medical & Pharmaceutical Journal of Chinese People’s Liberation Army

基　　金：河北省科学技术项目(162777134)

摘　　要：目的观察细胞免疫治疗中晚期肝癌的效果。方法选取2016年2—9月中国石油天然气集团公司中心医院肿瘤科接受治疗的中晚期肝癌105例,按治疗方法分为观察组54例和对照组51例。对照组采用重组人血管内皮抑制素注射液联合肝动脉栓塞化疗,观察组在对照组基础上加用细胞免疫治疗。观察两组治疗效果、生活质量及不良反应情况。结果观察组有效率、生活质量改善情况均优于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论细胞免疫治疗应用在中晚期肝癌,可提高有效率,改善生活质量,降低不良反应发生率。Objective To observe effect of cellular immunotherapy in treatment of patients with middle-advanced hepatocellular carcinoma. Methods A total of 105 patients with middle-advanced hepatocellular carcinoma admitted during February 2016 and September were divided into observation group( n = 54) and control group( n = 51) according to therapeutic methods. Control group was treated with recombinant human endostatin injection combined with hepatic arterial chemoembolization,while observation group was added with cellular immunotherapy on the basis of treatment for control group. Effects,life quality and incidence rate of adverse reaction were observed in two groups. Results The effective rate and improved condition of life quality in observation group were superior than those in control group( P <0. 05). There was no significant difference in incidence rate of adverse reaction between two groups( P > 0. 05). Conclusion The application of cellular immunotherapy in treatment of patients with middle-advanced hepatocellular carcinoma may significantly improve effective rate and life quality and reduce incidence rate of adverse reaction.

关 键 词：肝肿瘤 免疫疗法 过继 重组人血管内皮抑制素 肝动脉栓塞化疗 

分 类 号：R735.7[医药卫生—肿瘤]